While dHER2+AS15 ASCI stimulates the immunesystem to recognize and attack HER2+ tumor cells, lapatinib, a dualtyrosine kinase inhibitor that targets HER1 and HER2, blocks the growthsignaling of these cells.177. The gene discussed is ERBB2; the disease is neoplasm.